Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Impact Therapeutics Raises $30m In Series C Financing
Venture Capital

Impact Therapeutics Raises $30m In Series C Financing

by vcaonline.com posted 9months ago 66 views
IMPACT Therapeutics Raises $30 Million In Series C Financing NANJING, China, August 3, 2018-- IMPACT Therapeutics, Inc. (IMPACT), a China-based clinical-stage biopharmaceutical company dedicated to the discovery and development of "best-in-class" medicine for the treatment of cancer and other life-threatening diseases, today announced the completion of $30 million in series C financing. The series C round was led by Decheng Capital (Decheng), with participation from existing investor Lilly Asian Ventures (LAV). Proceeds from the series will be used for the clinical development of IMP4297, a potential best-in-class PARP inhibitor, and to advance IMPACT's integrated programs targeting DNA Damage Response (DDR).

In this article